Logo-apb
Adv Pharm Bull. 2022;12(1): 1-4.
doi: 10.34172/apb.2022.001
PMID: 35517880
PMCID: PMC9012934
Scopus ID: 85127162469
  Abstract View: 996
  PDF Download: 627
  Full Text View: 48

Editorial

Renin Angiotensin System and Covid-19 Infection

Francesco Ferrara 1* ORCID logo, Antonio Vitiello 2

1 Pharmaceutical Department, Asl Napoli 3 Sud, Dell’amicizia street, Nola, Naples, Italy.
2 Pharmaceutical Department, Usl Umbria 1, XIV Settembre street, Perugia, Italy.
*Corresponding Author: Email: ferrarafr@libero.it

Abstract

Purpose: The new coronavirus, called SARS-CoV-2, is responsible for the recent global pandemicCOVID-19. The status of the global pandemic COVID-19 is currently underway, and the virushas caused about 1.11 million deaths. Several SARS-CoV-2 vaccines are in phase 3 clinicaltrials. Pending the availability of safe and effective vaccines, pharmacological treatments areexperimental and aimed at avoiding the most serious complications of the infection.Methods: This article explores and describes the scientific evidence in the literature and thescientific pharmacological and molecular rationale to consider drugs that modulate the reninangiotensinsystem (RAS) system as therapeutic agents that if administered appropriately canhelp the host organism to fight SARS-CoV-2 infection.Results: It is known from the 2003 SARS epidemic that the critical receptor for SARS-CoV entryinto host cells is the angiotensin-converting enzyme 2 (ACE2), the strain involved in the currentSARS-CoV-2 epidemic is similar to the SARS-CoV strain involved in the 2002-2003 SARS epidemic.ACE-2 is part of the RAS system, the modulation of this enzyme could be of therapeutic efficacy.Conclusion: Depending on pharmacological knowledge, and epidemiological evidence inthe literature based on current knowledge of the mechanism of penetration of SARS-CoV-2 incells, and the role of ACE-2 in the inflammatory state of infection, therapeutic treatments thatmodulate RAS could be a weapon to fight COVID-19 infection.
First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 995

Your browser does not support the canvas element.


PDF Download: 627

Your browser does not support the canvas element.


Full Text View: 48

Your browser does not support the canvas element.

Submitted: 13 May 2020
Revision: 21 Oct 2020
Accepted: 23 Jan 2021
ePublished: 23 Jan 2021
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)